An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer

By Vaishampayan U.   Fontana J.   Du W.   Hussain M.  

Urology, Vol. 60, Iss. 6, 2002-12 ,pp. : 1050-1054

Elsevier

Access to resources Recommend Favorite

The NF-κB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?

By Paule Bernard  

World Journal of Urology, Vol. 25, Iss. 5, 2007-10 ,pp. : 477-489

Springer Publishing Company

Access to resources Recommend Favorite

Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer

By Benaim E.A.   Pace C.M.   Lam P.M.   Roehrborn C.G.  

Urology, Vol. 59, Iss. 1, 2002-01 ,pp. : 73-78

Elsevier

Access to resources Recommend Favorite

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

By Samelis G.F.   Skarlos D.   Bafaloukos D.   Kosmidis P.   Anagnostopoulos A.   Aravantinos G.   Dimopoulos M.A.  

Urology, Vol. 61, Iss. 6, 2003-06 ,pp. : 1211-1215

Elsevier

Access to resources Recommend Favorite

Acid phosphatase: defining a role in androgen-independent prostate cancer

By Steineck G.   Kelly W.K.   Mazumdar M.   Vlamis V.   Schwartz M.   Scher H.I.  

Urology, Vol. 47, Iss. 5, 1996-05 ,pp. : 719-726

Elsevier

Access to resources Recommend Favorite